Global biopharmaceutical company AstraZeneca remains confident in its business in China and is eyeing bigger opportunities in an increasingly open Chinese market. AstraZeneca's sales in China accounted for 20 percent of the total last year, and there the share is estimated to grow up to 30 percent, said Pascal Soriot, global chief executive officer (CEO) of the company. In 2018, AstraZeneca's sales totaled 3.8 billion U.S. dollars in China. This year, the sales in the first six months hit 2.4 billion U.S. dollars, making AstraZeneca the second-largest foreign drug-maker in the country.